LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 85

Search options

  1. Article ; Online: Editorial: Pathology and Oncology Research: addressing publication ethics issues.

    Tímár, József / Ladányi, Andrea / Sebestyén, Anna / Kopper, László

    Pathology oncology research : POR

    2024  Volume 30, Page(s) 1611691

    MeSH term(s) Humans ; Medical Oncology ; Biomedical Research
    Language English
    Publishing date 2024-02-14
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 1375979-6
    ISSN 1532-2807 ; 1219-4956
    ISSN (online) 1532-2807
    ISSN 1219-4956
    DOI 10.3389/pore.2024.1611691
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Comparative Effectiveness of Supervised and Home-Based Rehabilitation after Anterior Cruciate Ligament Reconstruction in Competitive Athletes.

    Syed, Rehan Iftikhar Bukhari / Hangody, Laszlo Rudolf / Frischmann, Gergely / Kós, Petra / Kopper, Bence / Berkes, István

    Journal of clinical medicine

    2024  Volume 13, Issue 8

    Abstract: Background: ...

    Abstract Background:
    Language English
    Publishing date 2024-04-12
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm13082245
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Hypoxia Signaling in Cancer: From Basics to Clinical Practice.

    Sebestyén, Anna / Kopper, László / Dankó, Titanilla / Tímár, József

    Pathology oncology research : POR

    2021  Volume 27, Page(s) 1609802

    Abstract: Cancer hypoxia, recognized as one of the most important hallmarks of cancer, affects gene expression, metabolism and ultimately tumor biology-related processes. Major causes of cancer hypoxia are deficient or inappropriate vascularization and systemic ... ...

    Abstract Cancer hypoxia, recognized as one of the most important hallmarks of cancer, affects gene expression, metabolism and ultimately tumor biology-related processes. Major causes of cancer hypoxia are deficient or inappropriate vascularization and systemic hypoxia of the patient (frequently induced by anemia), leading to a unique form of genetic reprogramming by hypoxia induced transcription factors (HIF). However, constitutive activation of oncogene-driven signaling pathways may also activate hypoxia signaling independently of oxygen supply. The consequences of HIF activation in tumors are the angiogenic phenotype, a novel metabolic profile and the immunosuppressive microenvironment. Cancer hypoxia and the induced adaptation mechanisms are two of the major causes of therapy resistance. Accordingly, it seems inevitable to combine various therapeutic modalities of cancer patients by existing anti-hypoxic agents such as anti-angiogenics, anti-anemia therapies or specific signaling pathway inhibitors. It is evident that there is an unmet need in cancer patients to develop targeted therapies of hypoxia to improve efficacies of various anti-cancer therapeutic modalities. The case has been opened recently due to the approval of the first-in-class HIF2α inhibitor.
    MeSH term(s) Animals ; Humans ; Hypoxia/physiopathology ; Neoplasms/immunology ; Neoplasms/pathology ; Neovascularization, Pathologic/immunology ; Neovascularization, Pathologic/pathology ; Signal Transduction ; Tumor Microenvironment
    Language English
    Publishing date 2021-05-03
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1375979-6
    ISSN 1532-2807 ; 1219-4956
    ISSN (online) 1532-2807
    ISSN 1219-4956
    DOI 10.3389/pore.2021.1609802
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts.

    Kopper, László

    Pathology oncology research : POR

    2012  Volume 18, Issue 4, Page(s) 743–747

    Abstract: Denosumab is a perfect example on the targeted anticancer therapy. The inhibition of RANKL activity suppressed the osteoclasts' resorptive function and so prevented skeletal related events. This effect is useful not only against bone metastases, but also ...

    Abstract Denosumab is a perfect example on the targeted anticancer therapy. The inhibition of RANKL activity suppressed the osteoclasts' resorptive function and so prevented skeletal related events. This effect is useful not only against bone metastases, but also in the treatment of other diseases caused by bone loss. In different solid tumors with bone metastasis the quality of life also improved, although the overall survival usually showed no change. On the market the main competitors for denosumab are still the bisphosphonates (questions of costs and reimbursement are not discussed) and some potential new agents e.g. Src kinases (as dasatinib, saracatinib, bosutinib), cathepsin K inhibitors, (e.g. odanacatib), and new selective estrogen receptor modulators (e.g. bazedoxifene, lasofoxifene). Nevertheless, today denosumab is one of the most powerful agents in bone-saving area.
    MeSH term(s) Antibodies, Monoclonal, Humanized/pharmacology ; Bone Density Conservation Agents/pharmacology ; Bone Neoplasms/drug therapy ; Bone Neoplasms/prevention & control ; Bone Neoplasms/secondary ; Bone Resorption/drug therapy ; Denosumab ; Humans ; Neoplasm Metastasis ; Osteoclasts/drug effects ; Osteoclasts/pathology ; RANK Ligand/antagonists & inhibitors
    Chemical Substances Antibodies, Monoclonal, Humanized ; Bone Density Conservation Agents ; RANK Ligand ; TNFSF11 protein, human ; Denosumab (4EQZ6YO2HI)
    Language English
    Publishing date 2012-05-16
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1375979-6
    ISSN 1532-2807 ; 1219-4956
    ISSN (online) 1532-2807
    ISSN 1219-4956
    DOI 10.1007/s12253-012-9538-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Evidence of Disruption in Neural Regeneration in Dry Eye Secondary to Rheumatoid Arthritis.

    Sonkodi, Balázs / Csorba, Anita / Marsovszky, László / Balog, Attila / Kopper, Bence / Nagy, Zoltán Zsolt / Resch, Miklós D

    International journal of molecular sciences

    2023  Volume 24, Issue 8

    Abstract: The purpose of our study was to analyze abnormal neural regeneration activity in the cornea through means of confocal microscopy in rheumatoid arthritis patients with concomitant dry eye disease. We examined 40 rheumatoid arthritis patients with variable ...

    Abstract The purpose of our study was to analyze abnormal neural regeneration activity in the cornea through means of confocal microscopy in rheumatoid arthritis patients with concomitant dry eye disease. We examined 40 rheumatoid arthritis patients with variable severity and 44 volunteer age- and gender-matched healthy control subjects. We found that all examined parameters were significantly lower (
    MeSH term(s) Humans ; Channelopathies/complications ; Dry Eye Syndromes/complications ; Arthritis, Rheumatoid/complications ; Cornea/innervation ; Corneal Keratocytes ; Microscopy, Confocal/methods ; Ion Channels
    Chemical Substances PIEZO1 protein, human ; Ion Channels
    Language English
    Publishing date 2023-04-19
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24087514
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Neural Regeneration in Dry Eye Secondary to Systemic Lupus Erythematosus Is Also Disrupted like in Rheumatoid Arthritis, but in a Progressive Fashion.

    Sonkodi, Balázs / Marsovszky, László / Csorba, Anita / Balog, Attila / Kopper, Bence / Nagy, Zoltán Zsolt / Resch, Miklós D

    International journal of molecular sciences

    2023  Volume 24, Issue 13

    Abstract: Our objective in this study was to analyze the aberrant neural regeneration activity in the cornea by means of in vivo confocal microscopy in systemic lupus erythematosus patients with concurrent dry eye disease. We examined 29 systemic lupus ... ...

    Abstract Our objective in this study was to analyze the aberrant neural regeneration activity in the cornea by means of in vivo confocal microscopy in systemic lupus erythematosus patients with concurrent dry eye disease. We examined 29 systemic lupus erythematosus patients and 29 age-matched healthy control subjects. Corneal nerve fiber density (CNFD, the number of fibers/mm
    MeSH term(s) Humans ; Dry Eye Syndromes ; Cornea/innervation ; Nerve Fibers ; Nerve Tissue ; Arthritis, Rheumatoid/complications ; Microscopy, Confocal
    Language English
    Publishing date 2023-06-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms241310680
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Disrupted Neural Regeneration in Dry Eye Secondary to Ankylosing Spondylitis-With a Theoretical Link between Piezo2 Channelopathy and Gateway Reflex, WDR Neurons, and Flare-Ups.

    Sonkodi, Balázs / Marsovszky, László / Csorba, Anita / Balog, Attila / Kopper, Bence / Keller-Pintér, Anikó / Nagy, Zoltán Zsolt / Resch, Miklós D

    International journal of molecular sciences

    2023  Volume 24, Issue 20

    Abstract: This study aimed at analyzing the corneal neural regeneration in ankylosing spondylitis patients using in vivo corneal confocal microscopy in correlation with Langerhans cell density, morphology, and dry eye parameters. Approximately 24 ankylosing ... ...

    Abstract This study aimed at analyzing the corneal neural regeneration in ankylosing spondylitis patients using in vivo corneal confocal microscopy in correlation with Langerhans cell density, morphology, and dry eye parameters. Approximately 24 ankylosing spondylitis subjects and 35 age- and gender-matched control subjects were enrolled. Data analysis showed that all corneal nerve-fiber descriptives were lower in the ankylosing spondylitis group, implicating disrupted neural regeneration. Peripheral Langerhans cell density showed a negative correlation with nerve fiber descriptions. A negative correlation between tear film break-up time and corneal nerve fiber total branch density was detected. The potential role of somatosensory terminal Piezo2 channelopathy in the pathogenesis of dry eye disease and ankylosing spondylitis is highlighted in our study, exposing the neuroimmunological link between these diseases. We hypothesized earlier that spinal neuroimmune-induced sensitization due to this somatosensory terminal primary damage could lead to Langerhans cell activation in the cornea, in association with downregulated Piezo1 channels on these cells. This activation could lead to a Th17/Treg imbalance in dry eye secondary to ankylosing spondylitis. Hence, the corneal Piezo2 channelopathy-induced impaired Piezo2-Piezo1 crosstalk could explain the disrupted neural regeneration. Moreover, the translation of our findings highlights the link between Piezo2 channelopathy-induced gateway to pathophysiology and the gateway reflex, not to mention the potential role of spinal wide dynamic range neurons in the evolution of neuropathic pain and the flare-ups in ankylosing spondylitis and dry eye disease.
    MeSH term(s) Humans ; Channelopathies/complications ; Cornea/pathology ; Dry Eye Syndromes/pathology ; Nerve Fibers/pathology ; Reflex ; Spondylitis, Ankylosing/pathology
    Chemical Substances PIEZO2 protein, human
    Language English
    Publishing date 2023-10-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms242015455
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Panitumumab: an arrow on target.

    Kopper, László

    Pathology oncology research : POR

    2010  Volume 16, Issue 2, Page(s) 143–148

    Abstract: Several options are available today in the treatment of advanced colorectal cancer: traditional chemotherapeutic regimens, targeted therapies, and their combinations. Panitumumab is a new, fully human anti-EGFR monoclonal antibody, what is well-tolerated, ...

    Abstract Several options are available today in the treatment of advanced colorectal cancer: traditional chemotherapeutic regimens, targeted therapies, and their combinations. Panitumumab is a new, fully human anti-EGFR monoclonal antibody, what is well-tolerated, effective as a single agent in chemotherapy refractory patients and in different combinations. The clinical response is restricted to tumors with wild-type RAS, therefore the RAS status should be checked before treatment.
    MeSH term(s) Animals ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Clinical Trials as Topic ; Colorectal Neoplasms/drug therapy ; Humans ; Panitumumab
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; Panitumumab (6A901E312A)
    Language English
    Publishing date 2010-04-30
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1375979-6
    ISSN 1532-2807 ; 1219-4956
    ISSN (online) 1532-2807
    ISSN 1219-4956
    DOI 10.1007/s12253-010-9257-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Neural Regeneration in Dry Eye Secondary to Systemic Lupus Erythematosus Is Also Disrupted like in Rheumatoid Arthritis, but in a Progressive Fashion

    Balázs Sonkodi / László Marsovszky / Anita Csorba / Attila Balog / Bence Kopper / Zoltán Zsolt Nagy / Miklós D. Resch

    International Journal of Molecular Sciences, Vol 24, Iss 10680, p

    2023  Volume 10680

    Abstract: Our objective in this study was to analyze the aberrant neural regeneration activity in the cornea by means of in vivo confocal microscopy in systemic lupus erythematosus patients with concurrent dry eye disease. We examined 29 systemic lupus ... ...

    Abstract Our objective in this study was to analyze the aberrant neural regeneration activity in the cornea by means of in vivo confocal microscopy in systemic lupus erythematosus patients with concurrent dry eye disease. We examined 29 systemic lupus erythematosus patients and 29 age-matched healthy control subjects. Corneal nerve fiber density (CNFD, the number of fibers/mm 2 ) and peripheral Langerhans cell morphology were lower ( p < 0.05) in systemic lupus erythematosus patients compared to the control group. Interestingly, corneal nerve branch density, corneal nerve fiber length, corneal nerve fiber total branch density, and corneal nerve fiber area showed a negative correlation with disease duration. A negative correlation was also demonstrated between average corneal nerve fiber density and central Langerhans cell density. This is in line with our hypothesis that corneal somatosensory terminal Piezo2 channelopathy-induced impaired Piezo2–Piezo1 crosstalk not only disrupts regeneration and keeps transcription activated, but could lead to Piezo1 downregulation and cell activation on Langerhans cells when we consider a chronic path. Hence, Piezo2 containing mechanosensory corneal nerves and dendritic Langerhans cells could also be regarded as central players in shaping the ocular surface neuroimmune homeostasis through the Piezo system. Moreover, lost autoimmune neuroinflammation compensation, lost phagocytic self-eating capacity, and lost transcription regulation, not to mention autoantibodies against vascular heparin sulfate proteoglycans and phospholipids, could all contribute to the progressive fashion of dry eye disease in systemic lupus erythematosus.
    Keywords dry eye disease ; systemic lupus erythematosus ; autoimmune disease ; Langerhans cell ; Piezo2 ; Piezo1 ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Subject code 610
    Language English
    Publishing date 2023-06-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article: Lapatinib: a sword with two edges.

    Kopper, László

    Pathology oncology research : POR

    2008  Volume 14, Issue 1, Page(s) 1–8

    Abstract: Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials ... ...

    Abstract Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Clinical Trials as Topic ; Drug Resistance, Neoplasm ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Female ; Humans ; Lapatinib ; Neoplasms/drug therapy ; Quinazolines/administration & dosage ; Quinazolines/adverse effects ; Quinazolines/pharmacokinetics ; Quinazolines/therapeutic use ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/metabolism ; Trastuzumab
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents ; Quinazolines ; Lapatinib (0VUA21238F) ; EGFR protein, human (EC 2.7.10.1) ; ERBB2 protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK)
    Language English
    Publishing date 2008-04-12
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1375979-6
    ISSN 1532-2807 ; 1219-4956
    ISSN (online) 1532-2807
    ISSN 1219-4956
    DOI 10.1007/s12253-008-9018-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top